• Cat-intel
  • MedIntelliX
  • Consulting
  • Resources
  • About Us
  • News
  • Careers
  • Contact Us
  • Login
    • English
    Chinese
    French
    Hindi

    Dermatophytic Onychomycosis Treatment Market

    ID: 10012
    128 Pages
    Research Team
    07/2025

    Dermatophytic Onychomycosis Treatment Market Research Report Information By Product Type (Tablets and Nail Paints), By Route of Administration (Oral and Topical), By Type (Prescribed and Over-the-Counter (OTC)), By Distribution Channel (Hospitals & Clinics, Retail Pharmacies, and Online Channels), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Ti...

    Share:
    ReportInfographic

    Purchase Options

    $ 4,950.0
    $ 5,950.0
    $ 7,250.0
    Compare License

    Market Summary

    Dermatophytic Onychomycosis Treatment Market Overview

    As per MRFR analysis, the Dermatophytic Onychomycosis Treatment Market Size was estimated at 4.96 (USD Billion) in 2024. The Dermatophytic Onychomycosis Treatment Market Industry is expected to grow from 5.36 (USD Billion) in 2025 to 10.62 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 7.90% during the forecast period (2025 - 2034).

    Dermatophytic Onychomycosis Treatment Market Overview 2025-2034

    Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

    Dermatophytic Onychomycosis Treatment Market Trends

      • Rising prevalence of dermatophytic onychomycosis is driving the market growth

    The prevalence of onychomycosis is one of the key factors driving the market's growth. Onychomycosis infections of the toenails occur far more frequently than those of the fingernails. The increased prevalence of dermatophyte-caused nail fungal infections and a sharp increase in prescriptions are expected to drive the market. According to a press release from Moberg Pharma AB, 35–40 million Americans have nail fungus, making up around 10% of the global population. This is likely to increase demand for the market for treating dermatophytic onychomycosis during the anticipated period. Diabetes is becoming more common, which is another factor behind the growth in dermatophytic infections.  The International Diabetes Federation estimates that 463 million people worldwide would have diabetes in 2019, which will help the industry grow.

    Pharmaceutical companies have increased their R&D spending significantly in order to discover novel therapies as a result of the increasing prevalence and lack of viable treatments. Many of the topical medications that are now on the market cannot reach the depths of the nail bed, making it impossible to entirely heal the infection. As a result, a lot of businesses are trying hard to find compounds that penetrate the nails deeper in an effort to overcome this difficulty. One biotech company, Hexima, is undertaking a phase I/lla clinical research on HXP124, a plant defensin anti-fungal molecule for the treatment of dermatophytic onychomycosis. Comparing the penetration rates of HXP124 to Kerydin and Jublia, it has been found to be higher. The market for medications to treat dermatophytic onychomycosis is expected to gain significantly from increased research funding and the introduction of promising therapeutic candidates. Thus, driving the Dermatophytic Onychomycosis Treatment market revenue.

    Dermatophytic Onychomycosis Treatment Market Segment Insights

    Dermatophytic Onychomycosis Treatment Product Type Insights

    The market segments of Dermatophytic Onychomycosis Treatment, based on product type includes tablets and nail paints. It is anticipated that the nail paints category will dominate the market for the entire projection period. The market is anticipated to grow as topical nail lacquers become more commonplace when compared to oral anti-fungal medications and Jublia usage rises. However, the COVID-19 pandemic's influence on Clenafin sales, particularly in Japan, has hurt the nail paints segment's revenue. Due to increased government initiatives to transition to generic medications, it is projected that the tablet market would expand.

    Dermatophytic Onychomycosis Treatment Route of Administration Insights

    The Dermatophytic Onychomycosis Treatment Market segmentation, based on route of administration, includes oral and topical. In 2022, the topical segment accounted for the largest share of the market. Due to the negative side effects of oral medications, such as liver damage, many podiatrists and dermatologists prefer to recommend topical treatments instead. This is likely to accelerate the growth of the tablets market, along with more research into the creation of topical medications. As opposed to topical solutions, oral drugs have better cure rates due to greater penetration and greater efficacy, which is the main driver of the segment's expansion throughout the forecast period.

    Dermatophytic Onychomycosis Treatment Type Insights

    The market segmentation of dermatophytic onychomycosis treatment, based on type, includes prescribed and over-the-counter (OTC). Due in large part to the steady move toward nail paints and rising sales of ciclopirox for the treatment of dermatophytic onychomycosis, the over-the-counter (OTC) segment dominated the market. The three main drivers of the growth of the prescription category are favorable health reimbursement, an increase in podiatrists, and the prevalence of dermatophytic onychomycosis. The government's decision to close non-emergency OPDs in hospitals and the decline in hospital visits have both had an adverse effect on the prescription segment.

    Figure 1: Dermatophytic Onychomycosis Treatment Market, by Type, 2022 & 2032 (USD Billion)Dermatophytic Onychomycosis Treatment Market, by Type, 2022 & 2032Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

    Dermatophytic Onychomycosis Treatment Distribution Channel Insights

    The Dermatophytic Onychomycosis Treatment Market segmentation, based on distribution channel, includes hospitals, retail pharmacies and online channels. The hospitals category held the largest share due to easy availability to the prescribed medicine and presence of skilled professionals for the treatment.

    Dermatophytic Onychomycosis Treatment Regional Insights

    By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. In the Regional section, North America was in first place in 2022 (45.8%). The main drivers of the market expansion in North America include the rise in onychomycosis prescriptions, more research, and rising demand for Jublia and Kerydin. The market in North America will grow as a result of the approximately 5 million prescriptions given annually in North America for the treatment of onychomycosis, according to a news release from Moberg Pharma AB. Further, the U.S. market of dermatophytic onychomycosis treatment held the largest market share, and the Canada Dermatophytic Onychomycosis Treatment market was the fastest growing market in the North America region.

    Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

    Figure 2: DERMATOPHYTIC ONYCHOMYCOSIS TREATMENT MARKET SHARE BY REGION 2022 (%)DERMATOPHYTIC ONYCHOMYCOSIS TREATMENT MARKET SHARE BY REGION 2022Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

    The Europe Dermatophytic Onychomycosis Treatment market is the second largest region. The demand for dermatophytic onychomycosis therapy is anticipated to rise in Europe as a result of the increased incidence of onychomycosis, attractive health reimbursement policies, and improved distribution of OTC pharmaceuticals through collaborations with retail pharmacies like Walmart, Walgreens, and others. According to a study that was published in the Journal of the European Academy of Dermatology and Venereology, onychomycosis is 4.3% prevalent in all of Europe. This is expected to stimulate the European market. Further, the German market of Dermatophytic Onychomycosis Treatment held the largest market share, and the UK market of Dermatophytic Onychomycosis Treatment was the fastest growing market in the European region.

    The Asia Pacific Dermatophytic Onychomycosis Treatment market is the fastest growing market over the forecast period. Due to the introduction of new products, the rising prevalence of diabetes, and the growing elderly population, the market in Asia Pacific is expected to soar. According to Kaken Pharmaceuticals Co., Ltd., Jublia will be made accessible as a treatment for dermatophytic onychomycosis in Hong Kong beginning in March 2020. The Asia Pacific market is expected to be stimulated by this. Factors including growing patient awareness, rising health spending, and expanding distribution networks are driving the market throughout the rest of the world. Further, China’s market of Dermatophytic Onychomycosis Treatment held the largest market share, and the Indian market of Dermatophytic Onychomycosis Treatment was the fastest growing market in the Asia-Pacific region.

    Dermatophytic Onychomycosis Treatment Key Market Players & Competitive Insights

    Leading market players are investing heavily in research and development in order to expand their Product Type lines, which will help the market of Dermatophytic Onychomycosis Treatment, grow even more. Market participants are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Dermatophytic Onychomycosis Treatment industry must offer cost-effective items.

    Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Dermatophytic Onychomycosis Treatment industry to benefit clients and increase the market sector. In recent years, the Dermatophytic Onychomycosis Treatment industry has offered some of the most significant advantages to medicine. Major players in the market of Dermatophytic Onychomycosis Treatment, including Bausch Health Companies Inc., Pfizer Inc., Galderma, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Cipla Inc., and Kaken pharmaceuticals Co., Ltd., are attempting to increase market demand by investing in research and development operations.

    Generic pharmaceutical goods are produced and distributed by Alembic Pharmaceuticals Ltd (APL), a pharmaceutical company. The company's product line consists of oral solids, oncology OSD, generic formulations, general and oncology injectables, and ophthalmic and dermatology goods. It provides goods for a range of medical treatments, including those for the heart, analgesics, genecology, cough and cold, gastroenterology, ophthalmology, anti-diabetics, orthopedic, urology, and dermatology. APL runs manufacturing sites in the Indian states of Gujarat and Sikkim as well as research labs in Vadodara, Hyderabad, and New Jersey. The company exports its goods to South Africa, Australia, Brazil, India, the US, Canada, and other parts of Europe. The headquarters of APL are in Gujarat, India's Vadodara. Aleor Dermaceuticals Limited (Aleor) received tentative approval from the US Food & Drug Administration (US FDA) for its abbreviated new drug application (ANDA) for Efinaconazole Topical Solution for the treatment of onychomycosis in the toenail in April 2021, according to an announcement made by Alembic Pharmaceuticals Limited (Alembic).

    Lupin Ltd. (Lupin) creates and produces biotechnology goods, active pharmaceutical ingredients (APIs), and generic and branded formulations. It has knowledge of cardiovascular, asthma, diabetes management, pediatrics, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory medications (NSAIDs), anti-TB, and cephalosporins. It also has knowledge of the central nervous system. The company engages in significant pharmaceutical research and development for the management of migraine, gastrointestinal, psoriasis, cardiovascular, TB, diabetes, inflammation, and other conditions. In addition, Lupin creates generic drugs with added value using its platform technology. The business runs production facilities in Brazil, Mexico, the US, and India together with its subsidiaries. Mumbai, Maharashtra, India is home to the headquarters of Lupin. Lupin Limited gained permission from the US Food and Drug Administration in February 2021 to market its Tavaborole Topical Solution for onychomycosis.

    Key Companies in the market of Dermatophytic Onychomycosis Treatment include

      • Galderma
      • GlaxoSmithKline plc
      • Janssen Pharmaceuticals, Inc.
      • Cipla Inc.
      • Kaken pharmaceuticals Co., Ltd.

    Dermatophytic Onychomycosis Treatment Industry Developments

    March 2020 - Jublia's introduction in Hong Kong was announced by Kaken Pharmaceuticals Co., Ltd..

    February 2019 - In accordance with a license agreement signed by Moberg Pharma AB and Bayer AG, Bayer AG is in charge of marketing, selling, and distributing MOB-015 in Europe.

    July 2018 - The introduction of NAILIN in Japan was announced by Sato Pharmaceutical Co., Ltd. and Eisai Co., Ltd.

    By way of example, Zydus Lifesciences was given the go ahead by the US health regulator to market an efinaconazole topical solution antifungal in 2022.

    Sanofi, in November 2021, announced the acquisition of Kadmon Holdings, which enhances the development and expansion of the General Medicines portfolio. Sanofi completed its acquisition of Kadmon through a merger where Sanofi’s wholly owned subsidiary was merged into Kadmon. The merger was executed under Section 251 of Delaware General Corporation Law, with Kadmon as the surviving corporation, now an indirect wholly owned subsidiary of Sanofi.

    Pfizer Inc. and Arena Pharmaceuticals Inc. revealed in December 2021 that they had settled an agreement that permits Pfizer to purchase Arena, a company that specializes in developing therapies to treat various immuno-inflammatory diseases in their clinical stage. Lupin Limited received FDA approval in July 2021 to market in the United States Tavaborole Topical Solution 5%.

    Dermatophytic Onychomycosis Treatment Market Segmentation

    Dermatophytic Onychomycosis Treatment Product Type Outlook

      • Tablets
      • Nail Paints

    Dermatophytic Onychomycosis Treatment Route of Administration Outlook

      • Oral
      • Topical

    Dermatophytic Onychomycosis Treatment Type Outlook

      • Prescribed
      • Over-the-Counter (OTC)

    Dermatophytic Onychomycosis Treatment Distribution Channel Outlook

      • Hospitals & Clinics
      • Retail Pharmacies
      • Online Channels

    Dermatophytic Onychomycosis Treatment Regional Outlook

      • North America
        • US.
        • Canada
      • Europe
        • Germany
        • France
        • UK
        • Italy
        • Spain
        • Rest of Europe
      • Asia-Pacific
        • China
        • Japan
        • India
        • Australia
        • South Korea
        • Australia
        • Rest of Asia-Pacific
      • Rest of the World
        • Middle East
        • Africa
        • Latin America

    Market Size & Forecast

    Report Attribute/Metric Details

    Market Size 2024

       4.96 (USD Billion)

    Market Size 2025

       5.36 (USD Billion)

    Market Size 2034

      10.62 (USD Billion)

    Compound Annual Growth Rate (CAGR)

       7.90 % (2025 - 2034)

    Report Coverage

    Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

    Base Year

    2024

    Market Forecast Period

    2025 - 2034

    Historical Data

    2020 - 2024
    Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
    Segments Covered Product Type, Route of Administration, Type, Distribution Channel, and Region
    Geographies Covered North America, Europe, Asia Pacific, and the Rest of the World
    Countries Covered The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
    Key Companies Profiled Bausch Health Companies Inc., Pfizer Inc., Galderma, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Cipla Inc., and Kaken pharmaceuticals Co., Ltd.
    Key Market Opportunities Gradual shift towards topical solutions
    Key Market Dynamics Rising prevalence of dermatophytic onychomycosis and presence of potential pipeline candidates

    Major Players

    Dermatophytic Onychomycosis Treatment Market Segmentation

    Dermatophytic Onychomycosis Treatment Product Type Outlook (USD Billion, 2018-2032)

    • Tablets

    • Nail Paints

    Dermatophytic Onychomycosis Treatment Route of Administration Outlook (USD Billion, 2018-2032)

    • Oral

    • Topical

    Dermatophytic Onychomycosis Treatment Type Outlook (USD Billion, 2018-2032)

    • Prescribed

    • Over-the-Counter (OTC)

    Dermatophytic Onychomycosis Treatment Distribution Channel Outlook (USD Billion, 2018-2032)

    • Hospitals

    • Retail Pharmacies

    • Online Channels

    Dermatophytic Onychomycosis Treatment Regional Outlook (USD Billion, 2018-2032)

    • North America Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type

        • Tablets

        • Nail Paints

      • Dermatophytic Onychomycosis Treatment by Route of Administration

        • Oral

        • Topical

      • Dermatophytic Onychomycosis Treatment by Type

        • Prescribed

        • Over-the-Counter (OTC)

      • Dermatophytic Onychomycosis Treatment by Distribution Channel

        • Hospitals

        • Retail Pharmacies

        • Online Channels

      • US Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type

        • Tablets

        • Nail Paints

      • Dermatophytic Onychomycosis Treatment by Route of Administration

        • Oral

        • Topical

      • Dermatophytic Onychomycosis Treatment by Type

        • Prescribed

        • Over-the-Counter (OTC)

      • Dermatophytic Onychomycosis Treatment by Distribution Channel

        • Hospitals

        • Retail Pharmacies

        • Online Channels

      • Canada Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type

        • Tablets

        • Nail Paints

      • Dermatophytic Onychomycosis Treatment by Route of Administration

        • Oral

        • Topical

      • Dermatophytic Onychomycosis Treatment by Type

        • Prescribed

        • Over-the-Counter (OTC)

      • Dermatophytic Onychomycosis Treatment by Distribution Channel

        • Hospitals

        • Retail Pharmacies

        • Online Channels

    • Europe Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type

        • Tablets

        • Nail Paints

      • Dermatophytic Onychomycosis Treatment by Route of Administration

        • Oral

        • Topical

      • Dermatophytic Onychomycosis Treatment by Type

        • Prescribed

        • Over-the-Counter (OTC)

      • Dermatophytic Onychomycosis Treatment by Distribution Channel

        • Hospitals

        • Retail Pharmacies

        • Online Channels

      • Germany Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type

        • Tablets

        • Nail Paints

      • Dermatophytic Onychomycosis Treatment by Route of Administration

        • Oral

        • Topical

      • Dermatophytic Onychomycosis Treatment by Type

        • Prescribed

        • Over-the-Counter (OTC)

      • Dermatophytic Onychomycosis Treatment by Distribution Channel

        • Hospitals

        • Retail Pharmacies

        • Online Channels

      • France Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type

        • Tablets

        • Nail Paints

      • Dermatophytic Onychomycosis Treatment by Route of Administration

        • Oral

        • Topical

      • Dermatophytic Onychomycosis Treatment by Type

        • Prescribed

        • Over-the-Counter (OTC)

      • Dermatophytic Onychomycosis Treatment by Distribution Channel

        • Hospitals

        • Retail Pharmacies

        • Online Channels

      • UK Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type

        • Tablets

        • Nail Paints

      • Dermatophytic Onychomycosis Treatment by Route of Administration

        • Oral

        • Topical

      • Dermatophytic Onychomycosis Treatment by Type

        • Prescribed

        • Over-the-Counter (OTC)

      • Dermatophytic Onychomycosis Treatment by Distribution Channel

        • Hospitals

        • Retail Pharmacies

        • Online Channels

      • Italy Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type

        • Tablets

        • Nail Paints

      • Dermatophytic Onychomycosis Treatment by Route of Administration

        • Oral

        • Topical

      • Dermatophytic Onychomycosis Treatment by Type

        • Prescribed

        • Over-the-Counter (OTC)

      • Dermatophytic Onychomycosis Treatment by Distribution Channel

        • Hospitals

        • Retail Pharmacies

        • Online Channels

      • Spain Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type

        • Tablets

        • Nail Paints

      • Dermatophytic Onychomycosis Treatment by Route of Administration

        • Oral

        • Topical

      • Dermatophytic Onychomycosis Treatment by Type

        • Prescribed

        • Over-the-Counter (OTC)

      • Dermatophytic Onychomycosis Treatment by Distribution Channel

        • Hospitals

        • Retail Pharmacies

        • Online Channels

      • Rest Of Europe Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type

        • Tablets

        • Nail Paints

      • Dermatophytic Onychomycosis Treatment by Route of Administration

        • Oral

        • Topical

      • Dermatophytic Onychomycosis Treatment by Type

        • Prescribed

        • Over-the-Counter (OTC)

      • Dermatophytic Onychomycosis Treatment by Distribution Channel

        • Hospitals

        • Retail Pharmacies

        • Online Channels

    • Asia-Pacific Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type

        • Tablets

        • Nail Paints

      • Dermatophytic Onychomycosis Treatment by Route of Administration

        • Oral

        • Topical

      • Dermatophytic Onychomycosis Treatment by Type

        • Prescribed

        • Over-the-Counter (OTC)

      • Dermatophytic Onychomycosis Treatment by Distribution Channel

        • Hospitals

        • Retail Pharmacies

        • Online Channels

      • China Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type

        • Tablets

        • Nail Paints

      • Dermatophytic Onychomycosis Treatment by Route of Administration

        • Oral

        • Topical

      • Dermatophytic Onychomycosis Treatment by Type

        • Prescribed

        • Over-the-Counter (OTC)

      • Dermatophytic Onychomycosis Treatment by Distribution Channel

        • Hospitals

        • Retail Pharmacies

        • Online Channels

      • Japan Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type

        • Tablets

        • Nail Paints

      • Dermatophytic Onychomycosis Treatment by Route of Administration

        • Oral

        • Topical

      • Dermatophytic Onychomycosis Treatment by Type

        • Prescribed

        • Over-the-Counter (OTC)

      • Dermatophytic Onychomycosis Treatment by Distribution Channel

        • Hospitals

        • Retail Pharmacies

        • Online Channels

      • India Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type

        • Tablets

        • Nail Paints

      • Dermatophytic Onychomycosis Treatment by Route of Administration

        • Oral

        • Topical

      • Dermatophytic Onychomycosis Treatment by Type

        • Prescribed

        • Over-the-Counter (OTC)

      • Dermatophytic Onychomycosis Treatment by Distribution Channel

        • Hospitals

        • Retail Pharmacies

        • Online Channels

      • Australia Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type

        • Tablets

        • Nail Paints

      • Dermatophytic Onychomycosis Treatment by Route of Administration

        • Oral

        • Topical

      • Dermatophytic Onychomycosis Treatment by Type

        • Prescribed

        • Over-the-Counter (OTC)

      • Dermatophytic Onychomycosis Treatment by Distribution Channel

        • Hospitals

        • Retail Pharmacies

        • Online Channels

      • Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type

        • Tablets

        • Nail Paints

      • Dermatophytic Onychomycosis Treatment by Route of Administration

        • Oral

        • Topical

      • Dermatophytic Onychomycosis Treatment by Type

        • Prescribed

        • Over-the-Counter (OTC)

      • Dermatophytic Onychomycosis Treatment by Distribution Channel

        • Hospitals

        • Retail Pharmacies

        • Online Channels

    • Rest of the World Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type

        • Tablets

        • Nail Paints

      • Dermatophytic Onychomycosis Treatment by Route of Administration

        • Oral

        • Topical

      • Dermatophytic Onychomycosis Treatment by Type

        • Prescribed

        • Over-the-Counter (OTC)

      • Dermatophytic Onychomycosis Treatment by Distribution Channel

        • Hospitals

        • Retail Pharmacies

        • Online Channels

      • Middle East Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type

        • Tablets

        • Nail Paints

      • Dermatophytic Onychomycosis Treatment by Route of Administration

        • Oral

        • Topical

      • Dermatophytic Onychomycosis Treatment by Type

        • Prescribed

        • Over-the-Counter (OTC)

      • Dermatophytic Onychomycosis Treatment by Distribution Channel

        • Hospitals

        • Retail Pharmacies

        • Online Channels

      • Africa Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type

        • Tablets

        • Nail Paints

      • Dermatophytic Onychomycosis Treatment by Route of Administration

        • Oral

        • Topical

      • Dermatophytic Onychomycosis Treatment by Type

        • Prescribed

        • Over-the-Counter (OTC)

      • Dermatophytic Onychomycosis Treatment by Distribution Channel

        • Hospitals

        • Retail Pharmacies

        • Online Channels

      • Latin America Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type

        • Tablets

        • Nail Paints

      • Dermatophytic Onychomycosis Treatment by Route of Administration

        • Oral

        • Topical

      • Dermatophytic Onychomycosis Treatment by Type

        • Prescribed

        • Over-the-Counter (OTC)

      • Dermatophytic Onychomycosis Treatment by Distribution Channel

        • Hospitals

        • Retail Pharmacies

        • Online Channels

    Market Trends

    Dermatophytic Onychomycosis Treatment Market Overview

    As per MRFR analysis, the Dermatophytic Onychomycosis Treatment Market Size was estimated at 4.96 (USD Billion) in 2024. The Dermatophytic Onychomycosis Treatment Market Industry is expected to grow from 5.36 (USD Billion) in 2025 to 10.62 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 7.90% during the forecast period (2025 - 2034).

    Dermatophytic Onychomycosis Treatment Market Overview 2025-2034

    Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

    Dermatophytic Onychomycosis Treatment Market Trends

      • Rising prevalence of dermatophytic onychomycosis is driving the market growth

    The prevalence of onychomycosis is one of the key factors driving the market's growth. Onychomycosis infections of the toenails occur far more frequently than those of the fingernails. The increased prevalence of dermatophyte-caused nail fungal infections and a sharp increase in prescriptions are expected to drive the market. According to a press release from Moberg Pharma AB, 35–40 million Americans have nail fungus, making up around 10% of the global population. This is likely to increase demand for...

    Market Segment Insights

    Smartphone Sensors Smartphone Type Insights

    The Smartphone Sensors market segmentation, based on smartphone type, includes standard smartphone, rugged smartphone, smartwatches, and other wearable. The standard smartphone segment dominated the market, accounting for the maximum market revenue. A smartphone is a mobile phone with a built-in computer and advanced features, such as web browsing and operating system, which are not associated with its counterpart. The rising mobile internet use, rising disposable income in developing countries, and high ownership of premium design smartphones are a few factors that are anticipated to grow smartphone sales. Smartphones are helped by a mobile operating system that offers advanced computing facilities. A smartphone can also work as a digital media player for uploading photos, videos, and music through a single interface.

    Smartphone Sensors Market, By Device Type Outlook, 2024 & 2035
    Get detailed insights about Dermatophytic Onychomycosis Treatment Market

    Smartphone Sensors Manufacturer Insights

    The Smartphone Sensors market segmentation, based on the manufacturer, includes Apple Inc., Samsung Electronics, Huawei Technology, Xiaomi Inc., Oppo, Sony Corporation, HMD Global, and others. The Apple Inc. segment generated the most revenue due to its superior quality. Apple’s iPhone stands out over all other smartphones in the market. Apple Inc. is the market leader because they use more sensors in their devices to provide unique features. For Instance: Apple’s iPhone 12 uses a lidar for depth sensing, proximity for 3D touch, a gyroscope for compass, GPS, face ID for biometrics, auto-off, a barometer, a magnetometer for compass & GPS, and an ambient light sensor for auto-dimming displays. The better user experience, increased accessibility, and more security these sensors offer consumers to boost the segment‘s growth.

    Smartphone Sensors Application Insights

    The Smartphone Sensors market segmentation, based on the manufacturer, includes Apple Inc., Samsung Electronics, Huawei Technology, Xiaomi Inc., Oppo, Sony Corporation, HMD Global, and others. The Apple Inc. segment generated the most revenue due to its superior quality. Apple’s iPhone stands out over all other smartphones in the market. Apple Inc. is the market leader because they use more sensors in their devices to provide unique features. For Instance: Apple’s iPhone 12 uses a lidar for depth sensing, proximity for 3D touch, a gyroscope for compass, GPS, face ID for biometrics, auto-off, a barometer, a magnetometer for compass & GPS, and an ambient light sensor for auto-dimming displays. The better user experience, increased accessibility, and more security these sensors offer consumers to boost the segment‘s growth.

    Smartphone Sensors Regional Insights

    The Smartphone Sensors market segmentation, based on the manufacturer, includes Apple Inc., Samsung Electronics, Huawei Technology, Xiaomi Inc., Oppo, Sony Corporation, HMD Global, and others. The Apple Inc. segment generated the most revenue due to its superior quality. Apple’s iPhone stands out over all other smartphones in the market. Apple Inc. is the market leader because they use more sensors in their devices to provide unique features. For Instance: Apple’s iPhone 12 uses a lidar for depth sensing, proximity for 3D touch, a gyroscope for compass, GPS, face ID for biometrics, auto-off, a barometer, a magnetometer for compass & GPS, and an ambient light sensor for auto-dimming displays. The better user experience, increased accessibility, and more security these sensors offer consumers to boost the segment‘s growth.

    Smartphone Sensors Market, By Device Type Outlook, 2024 & 2035
    Get detailed insights about Smartphone Sensors Market

    Smartphone Sensors Price Insights

    The Smartphone Sensors market segmentation, based on price, includes USD 300 to USD 500, USD 100 to USD 300, above USD 500, and under USD 100. The USD 300 to USD 500 segment dominated the market revenue in the projected period. Most smartphones sold in medium-end devices have a sensor within this range. For instance: Nubia launched a new flagship Android device powered by the latest Snapdragon 8Gen 2CPU. The OEM has also specified that this gadget, which peculiarly seems to go by the name Z50 even though its processor was the z40 Pro, will compete with the Xiaomi 13 and iQOO11 series with cutting-edge LPDDR5X RAM and storage with the most recent UFS 4.0 spec.

    Get more detailed insights about Dermatophytic Onychomycosis Treatment Market

    Key Players and Competitive Insights

    Leading market players are investing heavily in research and development to expand their product lines, which will help the Smartphone Sensors market, grow even more. Market participants are also undertaking various strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and growing market climate, the Smartphone Sensors industry must offer cost-effective items.

    Manufacturing locally to minimize operational costs is one of the key business tactics manufacturers use in the Smartphone Sensors industry to benefit clients and increase the market sector. In recent years, the Smartphone Sensors industry has offered manufacturers some of the most significant advantages. Major players in the Smartphone Sensors market, including MS AG (Austria), Broadcom Inc. (US), DYNA IMAGE Corporation (China), Murata Electronics Oy (Finland), NEXT Biometrics Group ASA (Norway), Omron Corporation (Japan), Samsung Electronics Co. Ltd. (South Korea), Sony Corporation (Japan)., and others, are attempting to increase market demand by investing in research and development operations.

    Samsung is dedicated to abiding by local laws and regulations and enforcing a strict code of conduct for all employees. Samsung adheres to a straightforward business tent: to usage its technology and expertise to develop top-notch goods and services that make a more cultured world. Samsung provides a high importance on its people and technologies to do this. For Instance: In January 2023, Samsung Electronics launched its new MICRO LED, Neo QLED, and Samsung OLED product lines, along with lifestyle products and accessories, before CES® 2023.

    Apple Inc. is a multinational American technology business with its main office in Cupertino, California. According to revenue, Apple will be the top technological business in the world in 2022, with US $ 394.3 billion in sales. According to market capitalization, Apple is the largest corporation in the world as of March 2023. For Instance: In September 2022, the iPhone 14 and iPhone 14 Plus, which come in two sizes, 6.1 and 6.7 inches and include a smart design, camera upgrades, and game-changing new safety measures, were introduced by Apple. The iPhone 14 and iPhone 14 Plus have a powerful camera system that incorporates the primary and front TrueDepth cameras, the Ultra Wide camera for uncommon perspectives, and the photonic engine, an enhanced picture pipeline.

    Key Companies in the Smartphone Sensors market include

    MS AG (Austria)
    MS AG (Austria)
    MS AG (Austria)
    MS AG (Austria)
    MS AG (Austria)
    MS AG (Austria)
    MS AG (Austria)

    Industry Developments

    • September 2022: Comcast and Samsung Electronics announced their partnership to create 5G Radio Access Network (RAN) technologies to enhance 5G connection for Xfinity Mobile and Comcast Business Mobile users in Comcast service zones. Samsung will provide 5G RAN technology, and Comcast will deploy Citizens Broadband Radio Service (CBRS) and 600 MHz spectrum to provide 5G access to consumer and business users in the US.
    • October 2022: Huawei announced the release of the newest antenna solutions, including the Maxwell platform and the X2 antenna series, for the subsequent 5G antenna innovation stage. The new technologies speed up 5G deployment by improving antenna and setup capabilities.

    Market Segmentation

    Smartphone Type Outlook

    • Standard Smartphone
    • Rugged Smartphone
    • Smartwatches
    • Other Wearable

    Price Outlook

    • USD 300 to USD 500
    • USD 100 to USD 300
    • Above USD 500
    • Under USD 100

    Manufacturer Outlook

    • Apple Inc.
    • Samsung Electronics
    • Huawei Technology
    • Xiaomi Inc.
    • Oppo
    • Sony Corporation
    • HMD Global

    Application Outlook

    • High-Level
    • Mid-Level
    • Low-Level

    Manufacturer Outlook

    North America
    • US
    • Canada
    Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
    Asia-Pacific
    • China
    • Japan
    • India
    • Italy
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    Rest of the World
    • Middle East
    • Africa
    • Latin America

    Report Scope

    Report Attribute/Metric Details

    Market Size 2024

       4.96 (USD Billion)

    Market Size 2025

       5.36 (USD Billion)

    Market Size 2034

      10.62 (USD Billion)

    Compound Annual Growth Rate (CAGR)

       7.90 % (2025 - 2034)

    Report Coverage

    Revenue Forecast, Competitive Landscape, Growth Factors, and Trends

    Base Year

    2024

    Market Forecast Period

    2025 - 2034

    Historical Data

    2020 - 2024
    Report Coverage Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
    Segments Covered Product Type, Route of Administration, Type, Distribution Channel, and Region
    Geographies Covered North America, Europe, Asia Pacific, and the Rest of the World
    Countries Covered The U.S., Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
    Key Companies Profiled Bausch Health Companies Inc., Pfizer Inc., Galderma, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Cipla Inc., and Kaken pharmaceuticals Co., Ltd.
    Key Market Opportunities Gradual shift towards topical solutions
    Key Market Dynamics Rising prevalence of dermatophytic onychomycosis and presence of potential pipeline candidates

    Market Highlights

    Author

    Aarti Dhapte
    Team Lead - Research

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM
    View All

    FAQs

    1. US: DERMATOPHYTIC ONYCHOMYCOSIS TREATMENT MARKET, BY PRODUCT TYPE, 2018-2032
    2. US: DERMATOPHYTIC ONYCHOMYCOSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION,
    3. ASIA-PACIFIC: DERMATOPHYTIC ONYCHOMYCOSIS TREATMENT MARKET, BY PRODUCT TYPE,
    4. SOUTH KOREA: DERMATOPHYTIC ONYCHOMYCOSIS TREATMENT MARKET, BY TYPE, 2018-2032
    5. SOUTH KOREA: DERMATOPHYTIC ONYCHOMYCOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL,
    6. REST OF THE WORLD: DERMATOPHYTIC ONYCHOMYCOSIS TREATMENT MARKET, BY PRODUCT TYPE,
    7. MIDDLE EAST: DERMATOPHYTIC ONYCHOMYCOSIS TREATMENT MARKET, BY TYPE, 2018-2032
    8. MIDDLE EAST: DERMATOPHYTIC ONYCHOMYCOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL,
    9. MARKET DYNAMICS FOR THE GLOBAL DERMATOPHYTIC ONYCHOMYCOSIS TREATMENT MARKET</span>
    10. BAUSCH HEALTH COMPANIES INC.: SWOT ANALYSIS </span>
    11. GALDERMA: FINANCIAL OVERVIEW SNAPSHOT</span>
    12. GLAXOSMITHKLINE PLC: SWOT ANALYSIS</span>
    13. JANSSEN PHARMACEUTICALS, INC..: SWOT ANALYSIS </span>
    14. KAKEN PHARMACEUTICALS CO., LTD.: FINANCIAL OVERVIEW SNAPSHOT </span>
    15. KONINKLIJKE PHILIPS N.V.: FINANCIAL OVERVIEW SNAPSHOT</span>

    Dermatophytic Onychomycosis Treatment Market Segmentation

    Dermatophytic Onychomycosis Treatment Product Type Outlook (USD Billion, 2018-2032)

    • Tablets
    • Nail Paints

    Dermatophytic Onychomycosis Treatment Route of Administration Outlook (USD Billion, 2018-2032)

    • Oral
    • Topical

    Dermatophytic Onychomycosis Treatment Type Outlook (USD Billion, 2018-2032)

    • Prescribed
    • Over-the-Counter (OTC)

    Dermatophytic Onychomycosis Treatment Distribution Channel Outlook (USD Billion, 2018-2032)

    • Hospitals
    • Retail Pharmacies
    • Online Channels

    Dermatophytic Onychomycosis Treatment Regional Outlook (USD Billion, 2018-2032)

    • North America Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type
        • Tablets
        • Nail Paints
      • Dermatophytic Onychomycosis Treatment by Route of Administration
        • Oral
        • Topical
      • Dermatophytic Onychomycosis Treatment by Type
        • Prescribed
        • Over-the-Counter (OTC)
      • Dermatophytic Onychomycosis Treatment by Distribution Channel
        • Hospitals
        • Retail Pharmacies
        • Online Channels

      • US Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type
        • Tablets
        • Nail Paints
      • Dermatophytic Onychomycosis Treatment by Route of Administration
        • Oral
        • Topical
      • Dermatophytic Onychomycosis Treatment by Type
        • Prescribed
        • Over-the-Counter (OTC)
      • Dermatophytic Onychomycosis Treatment by Distribution Channel
        • Hospitals
        • Retail Pharmacies
        • Online Channels

      • Canada Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type
        • Tablets
        • Nail Paints
      • Dermatophytic Onychomycosis Treatment by Route of Administration
        • Oral
        • Topical
      • Dermatophytic Onychomycosis Treatment by Type
        • Prescribed
        • Over-the-Counter (OTC)
      • Dermatophytic Onychomycosis Treatment by Distribution Channel
        • Hospitals
        • Retail Pharmacies
        • Online Channels

    • Europe Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type
        • Tablets
        • Nail Paints
      • Dermatophytic Onychomycosis Treatment by Route of Administration
        • Oral
        • Topical
      • Dermatophytic Onychomycosis Treatment by Type
        • Prescribed
        • Over-the-Counter (OTC)
      • Dermatophytic Onychomycosis Treatment by Distribution Channel
        • Hospitals
        • Retail Pharmacies
        • Online Channels

      • Germany Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type
        • Tablets
        • Nail Paints
      • Dermatophytic Onychomycosis Treatment by Route of Administration
        • Oral
        • Topical
      • Dermatophytic Onychomycosis Treatment by Type
        • Prescribed
        • Over-the-Counter (OTC)
      • Dermatophytic Onychomycosis Treatment by Distribution Channel
        • Hospitals
        • Retail Pharmacies
        • Online Channels

      • France Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type
        • Tablets
        • Nail Paints
      • Dermatophytic Onychomycosis Treatment by Route of Administration
        • Oral
        • Topical
      • Dermatophytic Onychomycosis Treatment by Type
        • Prescribed
        • Over-the-Counter (OTC)
      • Dermatophytic Onychomycosis Treatment by Distribution Channel
        • Hospitals
        • Retail Pharmacies
        • Online Channels

      • UK Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type
        • Tablets
        • Nail Paints
      • Dermatophytic Onychomycosis Treatment by Route of Administration
        • Oral
        • Topical
      • Dermatophytic Onychomycosis Treatment by Type
        • Prescribed
        • Over-the-Counter (OTC)
      • Dermatophytic Onychomycosis Treatment by Distribution Channel
        • Hospitals
        • Retail Pharmacies
        • Online Channels

      • Italy Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type
        • Tablets
        • Nail Paints
      • Dermatophytic Onychomycosis Treatment by Route of Administration
        • Oral
        • Topical
      • Dermatophytic Onychomycosis Treatment by Type
        • Prescribed
        • Over-the-Counter (OTC)
      • Dermatophytic Onychomycosis Treatment by Distribution Channel
        • Hospitals
        • Retail Pharmacies
        • Online Channels

      • Spain Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type
        • Tablets
        • Nail Paints
      • Dermatophytic Onychomycosis Treatment by Route of Administration
        • Oral
        • Topical
      • Dermatophytic Onychomycosis Treatment by Type
        • Prescribed
        • Over-the-Counter (OTC)
      • Dermatophytic Onychomycosis Treatment by Distribution Channel
        • Hospitals
        • Retail Pharmacies
        • Online Channels

      • Rest Of Europe Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type
        • Tablets
        • Nail Paints
      • Dermatophytic Onychomycosis Treatment by Route of Administration
        • Oral
        • Topical
      • Dermatophytic Onychomycosis Treatment by Type
        • Prescribed
        • Over-the-Counter (OTC)
      • Dermatophytic Onychomycosis Treatment by Distribution Channel
        • Hospitals
        • Retail Pharmacies
        • Online Channels

    • Asia-Pacific Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type
        • Tablets
        • Nail Paints
      • Dermatophytic Onychomycosis Treatment by Route of Administration
        • Oral
        • Topical
      • Dermatophytic Onychomycosis Treatment by Type
        • Prescribed
        • Over-the-Counter (OTC)
      • Dermatophytic Onychomycosis Treatment by Distribution Channel
        • Hospitals
        • Retail Pharmacies
        • Online Channels

      • China Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type
        • Tablets
        • Nail Paints
      • Dermatophytic Onychomycosis Treatment by Route of Administration
        • Oral
        • Topical
      • Dermatophytic Onychomycosis Treatment by Type
        • Prescribed
        • Over-the-Counter (OTC)
      • Dermatophytic Onychomycosis Treatment by Distribution Channel
        • Hospitals
        • Retail Pharmacies
        • Online Channels

      • Japan Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type
        • Tablets
        • Nail Paints
      • Dermatophytic Onychomycosis Treatment by Route of Administration
        • Oral
        • Topical
      • Dermatophytic Onychomycosis Treatment by Type
        • Prescribed
        • Over-the-Counter (OTC)
      • Dermatophytic Onychomycosis Treatment by Distribution Channel
        • Hospitals
        • Retail Pharmacies
        • Online Channels

      • India Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type
        • Tablets
        • Nail Paints
      • Dermatophytic Onychomycosis Treatment by Route of Administration
        • Oral
        • Topical
      • Dermatophytic Onychomycosis Treatment by Type
        • Prescribed
        • Over-the-Counter (OTC)
      • Dermatophytic Onychomycosis Treatment by Distribution Channel
        • Hospitals
        • Retail Pharmacies
        • Online Channels

      • Australia Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type
        • Tablets
        • Nail Paints
      • Dermatophytic Onychomycosis Treatment by Route of Administration
        • Oral
        • Topical
      • Dermatophytic Onychomycosis Treatment by Type
        • Prescribed
        • Over-the-Counter (OTC)
      • Dermatophytic Onychomycosis Treatment by Distribution Channel
        • Hospitals
        • Retail Pharmacies
        • Online Channels

      • Rest of Asia-Pacific Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type
        • Tablets
        • Nail Paints
      • Dermatophytic Onychomycosis Treatment by Route of Administration
        • Oral
        • Topical
      • Dermatophytic Onychomycosis Treatment by Type
        • Prescribed
        • Over-the-Counter (OTC)
      • Dermatophytic Onychomycosis Treatment by Distribution Channel
        • Hospitals
        • Retail Pharmacies
        • Online Channels

    • Rest of the World Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type
        • Tablets
        • Nail Paints
      • Dermatophytic Onychomycosis Treatment by Route of Administration
        • Oral
        • Topical
      • Dermatophytic Onychomycosis Treatment by Type
        • Prescribed
        • Over-the-Counter (OTC)
      • Dermatophytic Onychomycosis Treatment by Distribution Channel
        • Hospitals
        • Retail Pharmacies
        • Online Channels

      • Middle East Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type
        • Tablets
        • Nail Paints
      • Dermatophytic Onychomycosis Treatment by Route of Administration
        • Oral
        • Topical
      • Dermatophytic Onychomycosis Treatment by Type
        • Prescribed
        • Over-the-Counter (OTC)
      • Dermatophytic Onychomycosis Treatment by Distribution Channel
        • Hospitals
        • Retail Pharmacies
        • Online Channels

      • Africa Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type
        • Tablets
        • Nail Paints
      • Dermatophytic Onychomycosis Treatment by Route of Administration
        • Oral
        • Topical
      • Dermatophytic Onychomycosis Treatment by Type
        • Prescribed
        • Over-the-Counter (OTC)
      • Dermatophytic Onychomycosis Treatment by Distribution Channel
        • Hospitals
        • Retail Pharmacies
        • Online Channels

      • Latin America Outlook (USD Billion, 2018-2032)

      • Dermatophytic Onychomycosis Treatment by Product Type
        • Tablets
        • Nail Paints
      • Dermatophytic Onychomycosis Treatment by Route of Administration
        • Oral
        • Topical
      • Dermatophytic Onychomycosis Treatment by Type
        • Prescribed
        • Over-the-Counter (OTC)
      • Dermatophytic Onychomycosis Treatment by Distribution Channel
        • Hospitals
        • Retail Pharmacies
        • Online Channels
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Related Reports

    Global Reports
    Regional Reports
    Country Reports

    Customer Strories

    Watch Video

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Jongwon Byun

    Director, Research Operations
    Case Study

    Smartphone Motherboard Parts Manufacturing Research

    Smartphone Motherboard Parts Manufacturing Research